Press Releases
-
July 21, 2022
Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect the safety and efficacy of immune checkpoint inhibitor therapies. (more…)
-
June 28, 2022
Artizan Biosciences Signs Lease at Winchester Works in New Haven
Winchester Office LLC announced today it has signed a lease with Artizan Biosciences at Winchester Works, a technology and life sciences building anchored by New Haven’s Science Park and located across the street from Yale’s Science Hill. (more…)
-
March 29, 2022
Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform
Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating a new class of transformative precision therapeutics that target and block the root causes of diverse, serious diseases triggered by intestinal inflammation, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,299,790 that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform. (more…)
-
January 18, 2022
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
Artizan Biosciences, Inc., a precision medicine biotechnology company, today announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (“IBD”). (more…)
-
November 18, 2021
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development program. (more…)
-
October 18, 2021
Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer
Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer. (more…)
-
March 01, 2021
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease. Series A-2 led by Hatteras Venture Partners and Biohaven. Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors. (more…)
-
June 10, 2019
Artizan Biosciences Announces Corporate Progress and Financing
Finalized Series A funding, bringing total raised to date to $12MM to support proprietary platform that enables identification of disease-driving bacteria and development of therapies for inflammatory diseases. Appointed Paul Miller, PhD, as Chief Scientific Officer. Moved to specialized microbiology facility in New Haven’s Science Park. (more…)